Cancer testis (CT) antigens provide attractive targets for cancer-specific immunotherapy. Although CT genes are expressed in some normal tissues, such as the testis and in some cases placenta, these immunologically protected sites lack MHC I expression and as such, do not present 'self' antigens to T cells. To date, CT genes have been shown to be expressed in a range of solid tumours, but rarely in haematological malignancies. We have extended previous studies to investigate the expression of a comprehensive range of CT genes (MAGE-A1, -A3, -A6, -A12, BAGE, GAGE, HAGE, LAGE-1, NY-ESO-1 and RAGE) for their expression in a cohort of acute and chronic myeloid leukaemia patient samples. CT expression was not detected in 20 normal bone marrow or peripheral blood stem cell samples. In acute myeloid leukaemia (AML) nine of the 26 (35%) samples analysed expressed one or more of the CT genes with six of the samples (23%) expressing HAGE. In chronic myeloid leukaemia (CML) 24 of 42 (57%) presentation chronic myeloid leukaemia (CML) patient samples expressed one or more CT antigen with 23 expressing HAGE. We have shown that HAGE is frequently expressed in CML, and to a lesser extent in AML patient samples. This is the first demonstration of HAGE gene expression in myeloid leukaemia patients and the frequent expression of HAGE at disease presentation opens up the possibility of early immunotherapeutic treatments.
Introduction
Cancer testis (CT) antigens provide attractive targets for cancer-specific immunotherapy due to their cancer-specific expression. The function of CT genes, including MAGE, BAGE, GAGE, HAGE, LAGE-1, NY-ESO-1 and RAGE, is largely unknown, however, expression has been demonstrated in a wide range of solid tumours. [1] [2] [3] [4] [5] [6] [7] [8] Random promoter demethylation which is particularly marked with disease progression 4, 9 may account at least in part for the increased expression of the CT genes in later stage cancers.
Analysis of CT gene expression in haematological malignancies has predominantly focused on lymphoid tumours, however, in the non-lymphoid haematological malignancies, MAGE-A4 expression has been shown in Hodgkin's disease, 10 MAGE, BAGE, GAGE and LAGE-1 expression in multiple myeloma 11 and SCP1 expression in 5.7% AML and 23% chronic myeloid leukaemia (CML) patient samples. 12 Martelange et al 4 investigated 22 leukaemia patient samples (including nine acute myeloid leukaemia (AML), three CML, seven acute lymphoblastic leukaemia and three chronic lymphocytic leukaemia) for HAGE expression and found only two of seven acute lymphoblastic leukaemia samples expressed 
Materials and methods

Bone marrow collection and processing
Bone marrow and peripheral blood stem cells were collected from normal donors and patients with CML and AML attending the Department of Haematological Medicine, Denmark Hill Campus of Guy's, King's and St Thomas' School of Medicine following informed consent. All presentation samples were collected from patients prior to any treatment. Total white blood cells were isolated following red blood cell lysis (155 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA, room temperature, 30 min) and remaining white cells were washed twice with PBS.
RNA extraction and cDNA preparation
Total RNA was extracted from frozen cell pellets using a RNeasy Mini Kit (Qiagen Ltd, Crawley, UK) and 5 g of total RNA was used as a template for cDNA synthesis using a First Strand cDNA Synthesis Kit (MBI Fermentas, Helena Biosciences, Sunderland, UK) following the manufacturer's guidelines.
Reverse transcription-polymerase chain reaction (RT-PCR)
The integrity of the cDNA templates was ensured using ␤-actin RT-PCR analysis using standard primers and previously reported methods. 11 RT-PCR was carried out to investigate MAGE-A1, -A3, -A6, -A12, BAGE, GAGE, HAGE, LAGE-1, NY-ESO-1 and RAGE expression as described previously.
3,4,11
Figure 1
Serially diluted RNA was reverse transcribed and amplified with HAGE-specific primers to determine detectable levels of HAGE expression. RNA from the P39 cell line was serially diluted at ratios of 1:10, 1:100, 1:1000 and 1:10 000 into normal donor bone marrow RNA such that all total RNA concentrations were 500 ng. Samples were reverse transcribed and amplified with HAGE-specific primers to give products as follows: Assessments of the RT-PCR products were performed visually on ethidium bromide-stained 1% agarose gels. Primers were designed to flank introns so that products arising from genomic DNA contamination would be notable by their increased size. PCR reactions were also performed using genomic DNA to demonstrate the increased product size obtained from this template. None of the cDNA samples analysed showed evidence of genomic DNA contamination. Sensitivity of the assay was determined by RT-PCR analyses of serial dilutions of quantified patient RNA diluted in normal bone marrow donor RNA (1:10, 1:100, 1:1000, 1:10 000 dilutions) such that all starting sample sizes were 500 ng. Five hundred pg of positive RNA (1:1000 dilution) could be detected in each of our RT-PCR assays. All PCR reactions were RT-PCR analyses for the expression of the MAGE-A1, -A3, -A6, -A12, HAGE and ␤-actin genes were performed on patient and normal donor samples. Amplified products were visualized on a 1% agarose gel stained with 10 g/ml ethidium bromide. Products amplified by RT-PCR are shown in lanes 1 and 2: from AML patients at diagnosis; lanes 3-8: from CML patients at diagnosis and lanes 9 and 10: from normal donor bone marrow. Lane 11 shows the lack of an amplification product when RT-PCR was performed in the absence of cDNA template. Lane M contained the DNA size marker. Amplifications products of MAGE-A1, -A3, -A6, -A12, HAGE and ␤-actin transcripts are shown in rows A to F, respectively. Integrity of the RNA samples obtained from patient tissue was demonstrated using ␤-actin RT-PCR (row F). Data are representative of at least two independent RT-PCR reactions.
Leukemia performed on at least two independently prepared cDNAs for each sample. Samples were scored +++, ++, + or ± if the amount of amplified product was greater or equal to that obtained with the 1:1000, 1:100 and 1:10 dilutions of reference RNA, respectively. Undetectable levels of amplified products were scored negative. Expression of the ␤-actin gene was comparable with that of the positive control (undiluted RNA) for each sample.
Sequence analysis of RT-PCR products
When available up to 10 RT-PCR products from each primer set was sequenced to confirm their identity. Products were amplified using the Thermo Sequenase II dye terminator cycle sequencing premix kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) following the manufacturer's protocols. Sequencing reaction products were purified by ethanol precipitation and run on an ABI Prism 377 automated sequencer (PE Applied Biosystems, Cheshire, UK).
Results
CT gene expression in leukaemia cell lines and normal donor samples
RT-PCR analysis of seven myeloid cell lines (HL-60, K562, LAMA 84, NB4, P39, U937 and VLB) showed HAGE expression in six of them and expression of at least one of the MAGE genes in the same cell lines (the exception being Lama 84) (Table 1) . GAGE, LAGE-1 and RAGE expression were detected in one of seven lines each, whereas BAGE and NY-ESO-1 expression were not found in any. None of the 20 bone marrow or peripheral blood stem cell normal donor samples showed detectable levels of CT genes expression (Table 2) .
CT gene expression in myeloid leukaemia patients
HAGE transcripts were detected in 23 of 42 (55%) presentation CML patients in chronic phase, one of five (20%) accelerated phase and five of seven (71%) blast crisis CML patient samples and six of 26 (23%) AML patient samples (Tables 2,  3A and 3B; Figures 1 and 2) . The expression of MAGE-A3 and MAGE-A6 appeared to increase in blast crisis CML to six of seven (86%) and four of seven (57%) from one of 42 (2%) and four of 42 samples (10%), respectively, at diagnosis, although sample sizes were small at blast crisis. Transcripts from one or more of the CT genes were identified in 33 of 54 (61%) CML and nine of 26 (35%) AML cases tested. Sequence analyses of RT-PCR products confirmed the identity of all CT genes investigated.
Discussion
Expression of the CT antigens has been found in a range of solid tumour types but less frequently in haematological malignancies. Previously MAGE-A1, MAGE-A3 and SCP-1 expression have been described in myeloid leukaemia cell lines and patient samples [6] [7] [8] and we have extended these studies through the analyses of an extensive list of CT gene expression in a large cohort of AML and CML patient samples. We investigated the expression of MAGE-A1, -A3, -A6, -A12, Table 1 Cancer testis gene expression in seven myeloid leukaemia cell lines
Lineage MAGE-A1 MAGE-A3 MAGE-A6 MAGE-A12 BAGE GAGE HAGE LAGE-1 NY-ESO-1 RAGE
Samples were scored +++, ++, + or ± depending on whether the amount of amplified product was greater or equal to that obtained with the 1:1000, 1:100 and 1:10 dilutions of reference RNA, respectively. Undetectable levels of amplified products were scored negative. CML, chronic myeloid leukaemia at diagnosis; AML, acute myeloid leukaemia; +, detectable expression of the CT gene; −, no detectable expression of the CT gene. 
BAGE, GAGE, HAGE, LAGE-1, NY-ESO-1 and RAGE in 54
CML cases (42 chronic phase, five accelerated phase and seven blast crisis) and 26 AML cases. We did not find any of the CT genes to be expressed in 20 peripheral blood stem cell or bone marrow samples from normal donors. In contrast, we demonstrate frequent expression of HAGE in 55% of chronic phase CML patients at diagnosis (prior to any treatment) which further increased to 71% in blast cell crisis and a lower frequency of 23% in the AML patient samples tested. Expression of MAGE-A3 and -A6 were infrequent in chronic phase and appeared to occur later in disease progression in CML at blast crisis in the small number of samples tested. LAGE-1 and RAGE were not expressed in any of the tumours tested and at a low frequency in the cell lines. In addition, NY-ESO-1 was only detected in one of 26 AML cases tested and in none of the CML cases or leukaemia cell lines. BAGE expression was found in two of the 42 CML cases analysed at presentation. We demonstrate for the first time that BAGE and NY-ESO-1 are expressed, albeit infrequently, in myeloid leukaemias. Most notably we show that HAGE is expressed in a high proportion of chronic phase CML patients with an increasing frequency of expression in blast cell crisis.
In contrast to our findings, previous investigators have also studied MAGE gene expression in AML and CML cases 13 and found that MAGE-A1, -A2, -A3, -A4, -A6 and -A12 were not expressed in 22 CML (eight chronic phase and 14 patients in accelerated phase) or 72 AML (six relapsed or refractory AML). We found that six of seven blast crisis samples expressed MAGE-A3 while one of five accelerated phase and four of seven blast crisis CML cases expressed MAGE-A6. However, early in disease progression we also found MAGE-A1, -A3, -A6 and -A12 expression to be infrequent in both AML and CML patient samples. The difference in frequency of MAGE-A3 and -A6 expression in our patient samples compared with those published by Chambost et al may be explained by the small sample sizes at blast crisis and the disease stages investigated by each group. We examined 42 CML patients in chronic phase for MAGE-A3 and -A6 expression and found only one of 42 expressed MAGE-A3 and four of 42 expressed MAGE-A6, respectively, while Chambost found neither expressed in eight chronic phase samples. At accelerated phase we found none of five and one of five patient samples expressed MAGE-A3 and MAGE-A6, respectively, while Chambost et al found none of 14 expressed either gene. Chambost et al did not examine any CML patient samples at blast crisis where we found six of seven and four of seven patient samples expressed MAGE-A3 and -A6, respectively. However, our sample size at blast crisis was small and further investigations are necessary to determine the true frequency of MAGE-A3 and -A6 expression in blast crisis.
The HAGE gene shows similar patterns of expression to the MAGE, BAGE, GAGE, NY-ESO-1 and LAGE-1 genes with strong expression in many tumour samples and in testis and either no expression or very low levels of expression (at least 100 times lower) in other normal tissues.
1,2,4-8 HAGE is expressed in many tumours of various histological types 4 and
